ACAT抑制剂HL-004对喂食普通饲料仓鼠的降血脂作用。
The hypolipidemic action of the ACAT inhibitor HL-004 in hamsters fed normal chow.
作者信息
Murakami S, Ohta Y, Asami Y, Yamagishi I, Toda Y, Sato M, Tomisawa K
机构信息
Medicinal Research Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama, Japan.
出版信息
Gen Pharmacol. 1996 Dec;27(8):1383-6. doi: 10.1016/s0306-3623(96)00070-5.
PMID:9304411
Abstract
- A novel ACAT (acyl-CoA: cholesterol acyltransferase) inhibitor, HL-004, exhibited a strong inhibitory effect on the hepatic and intestinal ACAT, but was less effective on the adrenal ACAT in vitro. 2. HL-004 selectively decreased serum VLDL cholesterol, and inhibited hepatic ACAT activity in hamsters fed normal chow. 3. These results suggest that the cholesterol-lowering effect of HL-004 can be attributed to a decrease in hepatic VLDL secretion via inhibition of ACAT.
摘要
- 一种新型的酰基辅酶A：胆固醇酰基转移酶（ACAT）抑制剂HL-004，在体外对肝脏和肠道的ACAT表现出强烈的抑制作用，但对肾上腺ACAT的作用较弱。2. HL-004选择性地降低了血清极低密度脂蛋白胆固醇（VLDL胆固醇），并抑制了喂食普通饲料的仓鼠的肝脏ACAT活性。3. 这些结果表明，HL-004的降胆固醇作用可归因于通过抑制ACAT减少肝脏VLDL的分泌。
Zotero 插件